Usage of spacers in respiratory laboratories and the delivered salbutamol dose of spacers available in Australia and New Zealand

Background and objective: Purchase and disinfection costs together with medication delivery factors may influence the choice of drug delivery options. This study assessed salbutamol delivery habits used in respiratory laboratories and quantified the delivered salbutamol dose of locally available spa...

Full description

Bibliographic Details
Main Authors: Hall, Graham, Annese, T., Looi, K., Devadason, S.
Format: Journal Article
Published: Wiley-Blackwell Publishing Asia 2011
Online Access:http://hdl.handle.net/20.500.11937/54259
_version_ 1848759326409228288
author Hall, Graham
Annese, T.
Looi, K.
Devadason, S.
author_facet Hall, Graham
Annese, T.
Looi, K.
Devadason, S.
author_sort Hall, Graham
building Curtin Institutional Repository
collection Online Access
description Background and objective: Purchase and disinfection costs together with medication delivery factors may influence the choice of drug delivery options. This study assessed salbutamol delivery habits used in respiratory laboratories and quantified the delivered salbutamol dose of locally available spacers. Methods: An online survey was used to obtain data on disinfection processes, costs and delivery device choices. The delivered dose of six commercial spacers was assessed. Particle size distribution of salbutamol (Ventolin, GSK, 100 µg/actuation) from six spacers of each type was measured by quantifying the amount of drug (µg) deposited on each stage of an Anderson Cascade Impactor (ACI) using UV spectrophotometry. Clinical conditions were simulated using a flow volume simulator (FVS) and delivery of salbutamol via a pressurized metered dose inhaler and spacer to a low-resistance filter was measured. Results: Fifty survey responses were obtained, with 37 (74%) using ≥1 type of spacer of which 92% processed single use spacers. The most commonly used spacers were Volumatic (n = 24), Breath-a-tech (n = 8) and Space Chamber (n = 7). The median disinfection cost was $2.45. Delivered salbutamol dose varied significantly and ranged from 16.98 to 38.28 µg with the ACI and 22.56 to 58.82 µg with the FVS. Using the FVS, small-volume spacers delivered similar doses (22.56 to 28.46 µg), while large-volume spacers delivery was more varied (24.31 to 58.82 µg). Conclusions: The majority of respiratory laboratories had not updated re-processing policies to comply with new regulations. The delivered salbutamol dose varied significantly and this might effect the choice of preferred spacer type.
first_indexed 2025-11-14T09:58:06Z
format Journal Article
id curtin-20.500.11937-54259
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:58:06Z
publishDate 2011
publisher Wiley-Blackwell Publishing Asia
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-542592017-09-29T06:11:13Z Usage of spacers in respiratory laboratories and the delivered salbutamol dose of spacers available in Australia and New Zealand Hall, Graham Annese, T. Looi, K. Devadason, S. Background and objective: Purchase and disinfection costs together with medication delivery factors may influence the choice of drug delivery options. This study assessed salbutamol delivery habits used in respiratory laboratories and quantified the delivered salbutamol dose of locally available spacers. Methods: An online survey was used to obtain data on disinfection processes, costs and delivery device choices. The delivered dose of six commercial spacers was assessed. Particle size distribution of salbutamol (Ventolin, GSK, 100 µg/actuation) from six spacers of each type was measured by quantifying the amount of drug (µg) deposited on each stage of an Anderson Cascade Impactor (ACI) using UV spectrophotometry. Clinical conditions were simulated using a flow volume simulator (FVS) and delivery of salbutamol via a pressurized metered dose inhaler and spacer to a low-resistance filter was measured. Results: Fifty survey responses were obtained, with 37 (74%) using ≥1 type of spacer of which 92% processed single use spacers. The most commonly used spacers were Volumatic (n = 24), Breath-a-tech (n = 8) and Space Chamber (n = 7). The median disinfection cost was $2.45. Delivered salbutamol dose varied significantly and ranged from 16.98 to 38.28 µg with the ACI and 22.56 to 58.82 µg with the FVS. Using the FVS, small-volume spacers delivered similar doses (22.56 to 28.46 µg), while large-volume spacers delivery was more varied (24.31 to 58.82 µg). Conclusions: The majority of respiratory laboratories had not updated re-processing policies to comply with new regulations. The delivered salbutamol dose varied significantly and this might effect the choice of preferred spacer type. 2011 Journal Article http://hdl.handle.net/20.500.11937/54259 10.1111/j.1440-1843.2011.01928.x Wiley-Blackwell Publishing Asia restricted
spellingShingle Hall, Graham
Annese, T.
Looi, K.
Devadason, S.
Usage of spacers in respiratory laboratories and the delivered salbutamol dose of spacers available in Australia and New Zealand
title Usage of spacers in respiratory laboratories and the delivered salbutamol dose of spacers available in Australia and New Zealand
title_full Usage of spacers in respiratory laboratories and the delivered salbutamol dose of spacers available in Australia and New Zealand
title_fullStr Usage of spacers in respiratory laboratories and the delivered salbutamol dose of spacers available in Australia and New Zealand
title_full_unstemmed Usage of spacers in respiratory laboratories and the delivered salbutamol dose of spacers available in Australia and New Zealand
title_short Usage of spacers in respiratory laboratories and the delivered salbutamol dose of spacers available in Australia and New Zealand
title_sort usage of spacers in respiratory laboratories and the delivered salbutamol dose of spacers available in australia and new zealand
url http://hdl.handle.net/20.500.11937/54259